There are currently 14 active clinical trials seeking participants for Eczema research studies. The states with the highest number of trials for Eczema participants are Florida, California, Texas and Ontario.
Effects of Treatments on Atopic Dermatitis
NCT01631617
Recruiting
Background: - Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin. Objectives: - To study the effect of eczema treatments on skin bacteria. Eligibility: Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis. Healthy volunteers between 18 and 40 years of age with no history of eczema. Design... Read More
Gender:
All
Ages:
Between 2 years and 50 years
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases
Register for Updates
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483
Recruiting
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis
Gender:
All
Ages:
Between 6 months and 18 years
Trial Updated:
06/19/2024
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +96 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
06/19/2024
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +98 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Cardamom and Topical Roseomonas in Atopic Dermatitis
NCT06096857
Recruiting
Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems. No cure exists for AD. Researchers know that people with AD have different kinds of harmless bacteria on their skin than do people without AD. They want to see if adding a harmless bacteria (Roseomonas mucosa) to the skin can help people with AD. Objective:... Read More
Gender:
All
Ages:
Between 2 years and 100 years
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878
Recruiting
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema. Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study. We also wish to enroll children and adults aged 2-40 who... Read More
Gender:
All
Ages:
Between 2 years and 100 years
Trial Updated:
06/05/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema, Ichthyosis Vulgaris
Register for Updates
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
NCT06436183
Recruiting
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2024
Locations: Medical Dermatology Specialists, PC/US Dermatology Partners, Phoenix, Arizona +27 locations
Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Register for Updates
Seal, Stopping Eczema and Allergy Study
NCT03742414
Recruiting
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Gender:
All
Ages:
Between 1 week and 12 weeks
Trial Updated:
05/08/2024
Locations: Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto, California +4 locations
Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Register for Updates
Bone Health in Patients With Atopic Dermatitis
NCT03800004
Recruiting
This study examines the bone health in children with atopic dermatitis
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
03/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
NCT01782703
Recruiting
Atopic dermatitis (AD), also known as eczema, is the most common inflammatory skin disorder of children, affecting 10-20% of children and 1-2% of adults. This skin disorder can be associated with unbearable itchiness and an increased susceptibility to skin infections. The cause of AD is currently poorly understood; therefore, there are no targeted treatment options at present. There have been recent studies in adults with AD that explain the cause and give us new routes to investigate treatment... Read More
Gender:
All
Ages:
Between 0 months and 17 years
Trial Updated:
03/11/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +3 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
NCT00177268
Recruiting
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Register for Updates
PatientSpot Formerly Known as ArthritisPower
NCT03840928
Recruiting
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psor... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
12/12/2023
Locations: Global Healthy Living Foundation, Upper Nyack, New York
Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Register for Updates
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
NCT05938478
Recruiting
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy. The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differences in pregnancy and infant outcomes compared to women with atopic dermatitis who have not been exposed to tralokinumab during pregnancy. Participants are not required to take tralokinumab during the s... Read More
Gender:
Female
Ages:
All
Trial Updated:
07/03/2023
Locations: University of California San Diego (UCSD), La Jolla, California
Conditions: Atopic Dermatitis, Eczema
Register for Updates